ADAR1 Capital Management »

Alkermes shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Alkermes (ALKS) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Alkermes

Tip: Access up to 7 years of quarterly data

All positions including Alkermes held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alkermes by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $2.1M 74k 27.99
2024-06-30 $4.7M 197k 24.10
2024-03-31 $4.2M 157k 27.07

More positions owned by ADAR1 Capital Management

Cytokinetics Com New (CYTK)
Protagonist Therapeutics (PTGX)
Bridgebio Pharma (BBIO)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Ascendis Pharma A/s Sponsored Adr (ASND)
Zura Bio Class A Ord Shs (ZURA)
Zai Lab Adr (ZLAB)
Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Aa Mission Acquisition Corp Ord Shs Cl A (AAM)
Mineralys Therapeutics (MLYS)
Syndax Pharmaceuticals (SNDX)

View all positions for ADAR1 Capital Management

Top funds holding Alkermes

BlackRock
Vanguard Group
T. Rowe Price Associates
Wellington Management Company
State Street Corporation
Rtw Investments
Renaissance Technologies
Baker Bros. Advisors
Geode Capital Management
Deep Track Capital
Pacer Advisors
PRIMECAP Management Company
American Century Companies
Commodore Capital
Dimensional Fund Advisors

View all funds holding Alkermes